Compare · DHR vs IQV
DHR vs IQV
Side-by-side comparison of Danaher Corporation (DHR) and IQVIA Holdings Inc. (IQV): market cap, price performance, sector, and recent activity on the wire.
Summary
- DHR operates in Industrials, while IQV operates in Health Care - the two are in different parts of the market.
- DHR is the larger of the two at $155.75B, about 3.5x IQV ($44.09B).
- Over the past year, DHR is up 23.1% and IQV is up 53.7% - IQV leads by 30.6 points.
- IQV has been more active in the news (6 items in the past 4 weeks vs 4 for DHR).
- Both have 25 recent analyst ratings on file.
- Company
- Danaher Corporation
- IQVIA Holdings Inc.
- Price
- $223.29-0.17%
- $271.72-1.21%
- Market cap
- $155.75B
- $44.09B
- 1M return
- +3.72%
- +3.88%
- 1Y return
- +23.12%
- +53.71%
- Industry
- Industrial Machinery/Components
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NYSE
- IPO
- 2013
- News (4w)
- 4
- 6
- Recent ratings
- 25
- 25
Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest DHR
- Danaher Schedules Third Quarter 2026 Earnings Conference Call
- Integrated DNA Technologies and Aldevron Launch New Cas9 mRNA Solutions to Accelerate Path from Gene Editing Research to Development
- Danaher Announces Quarterly Dividend
- UBS resumed coverage on Danaher with a new price target
- President & CEO Blair Rainer sold $12,736,095 worth of shares (58,255 units at $218.63) (SEC Form 4)
- Executive Vice President Riley Christopher Paul was granted 41,072 shares, increasing direct ownership by 201% to 61,472 units (SEC Form 4)
- SEC Form 4 filed by EVP & Chief Financial Officer Gugino Matthew E
- SEC Form 4 filed by SVP-Chief Legal Officer Leiken Jonathan
- SVP, Chief Science Officer Gutierrez-Ramos Jose-Carlos was granted 13,477 shares, increasing direct ownership by 71% to 32,495 units (SEC Form 4)
- SEC Form 4 filed by Executive Vice President Sawyer Montgomery Julie A
Latest IQV
- IQVIA Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Announces Pricing of Senior Notes
- IQVIA Announces Offering of Senior Notes
- Officer Berkshire James G. exercised 5,381 shares at a strike of $131.82, sold $697,228 worth of shares (2,668 units at $261.33) and returned $709,558 worth of shares to the company (2,713 units at $261.54) (SEC Form 4)
- IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
- IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
- IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
- IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
- Officer Staub W Richard sold $1,279,740 worth of shares (5,500 units at $232.68), decreasing direct ownership by 29% to 13,312 units (SEC Form 4)